2008: Vasculitis II
Search or Browse by Day

Vasculitis II

Tuesday, October 28, 2008
1855
Validation of a new version of the Birmingham Vasculitis Activity Score
1856
Cardiovascular outcomes in ANCA associated Vasculitis
1857
The Incidence Of Renal Vasculitis In Southern Sweden
1858
Epidemiology of ANCA-associated Vasculitis in the UK - a 20-year Study
1859
ANCA Testing in a General Reference Centre: Poor Return and Need for Nomenclature Review
1860
An Endoscopic Proposal to Evaluate Active Nasal Lesions in Wegener Granulomatosis (WG) with High Histopathological Correlation
1861
Anti-myeloperoxidase Antibodies Are A Useful Marker Of Disease Activity In Anca-associated Vasculitides
1862
Polymorphisms in the PRTN3 Gene Predict the Development of Wegener’s Granulomatosis but are not Associated with anti-Pr3 Antibody Production
1863
Co-expression of CD177 and Membrane Proteinase 3 on Neutrophils in ANCA-Associated Vasculitis: anti-PR3 Mediated Neutrophil Activation is Independent of CD177 Expression
1864
Elevated Levels of Serum Macrophage Migration Inhibitory Factor (MIF) in Patients with Microscopic Polyangiitis
1865
Urinary Cd4 Effector Memory T-cells As A Measure Of Renal Disease Activity In Anca-associated Vasculitis
1866
Eotaxin-3 Is Involved In Churg-strauss Syndrome
1867
Long-term outcomes and prognostic factors of Microscopic Polyangiitis: A Systematic Review
1868
Damage Caused by Wegener’s Granulomatosis: Data from a Multicenter Longitudinal Cohort
1869
Assessment of Damage in Vasculitis: Expert Ratings of Damage
1870
Morbidity and Mortality of Wegener’s Granulomatosis: Data from a Current Multicenter Longitudinal Cohort
1871
Characteristics and Treatment Strategies for the Wegener’s Granulomatosis (WG) and Microscopic Polyangiitis (MPA) Patients Recruited for the WEGENT Trial and Not Achieving Remission on Corticosteroids (CS) and Intravenous Cyclophosphamide (IV-CYC) I
1872
Rituximab Suppresses Systemic Inflammation, but has no effect on Airway Stenosis in Wegener`s granulomatosis
1873
Comparison of Infliximab and Rituximab in Wegener’s Granulomatosis (WG) Refractory to Steroids and Immunosuppressants: a Prospective, Randomized Study on 21 Patients
1874
HLA-B5(1) and Risk of Behçet's Disease: A Systematic Review and Meta-Analysis of Genetic Association Studies
1875
Behcet’s Syndrome Activity Score (BSAS): A New Disease Activity Assessment Tool, Composed Of Patient-derived Measures Only, Is Strongly Correlated With The Behcet's Disease Current Activity Form (BDCAF)
1876
Pulmonary Artery Aneurysm Screening in Patients with Behcet’s Disease
1877
Distribution of Killer Immunoglobulin-like Receptor 3DL1/3DS1 Alelles in Behcet’s Disease
1878
Validation of the International Criteria for Behcet’s Disease (ICBD) in Iran
1879
Cerebral Venous Thrombosis In BehçEt’S Disease
1880
Essential Cryofibrinogenemia: New Insights Into Clinical And Pathogenic Features
1881
Clinical Characteristics and Comparison of Treatment Outcomein Patients with Behcet’s Disease Undergoing Aortic Valve Replacement Due to Aortic Regurgitation
1882
Short-term And Long-term Efficacy Of Anti-TNF-α Antibody Infliximab On Refractory Entero-BehçEt's Disease
1883
Gynecologic Vasculitis, An Analysis of 163 Patients
See more of: ACR Abstract Submission Poster Sessions
<< Previous Session Level | Next Session Level >>